Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, reports.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Separately, HC Wainwright began coverage on Aclaris Therapeutics in a research note on Tuesday, April 27th. They issued a “buy” rating on the stock.

NASDAQ:ACRS traded down $1.37 during trading hours on Tuesday, reaching $23.55. The company’s stock had a trading volume of 28,089 shares, compared to its average volume of 2,373,070. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.54 and a current ratio of 4.54. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -17.66 and a beta of 1.20. The firm has a 50-day simple moving average of $25.97 and a 200-day simple moving average of $14.56. Aclaris Therapeutics has a 1 year low of $1.10 and a 1 year high of $30.38.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Wednesday, February 24th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.01. Aclaris Therapeutics had a negative return on equity of 104.00% and a negative net margin of 941.07%. The firm had revenue of $1.58 million for the quarter, compared to analysts’ expectations of $1.32 million. Equities analysts anticipate that Aclaris Therapeutics will post -1.17 earnings per share for the current fiscal year.

In other Aclaris Therapeutics news, CFO Frank Ruffo sold 27,339 shares of the business’s stock in a transaction dated Monday, April 26th. The shares were sold at an average price of $25.80, for a total value of $705,346.20. Following the transaction, the chief financial officer now owns 209,059 shares in the company, valued at $5,393,722.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.20% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. bought a new position in Aclaris Therapeutics during the 1st quarter valued at approximately $204,000. Dorsey Wright & Associates raised its holdings in shares of Aclaris Therapeutics by 135.0% during the first quarter. Dorsey Wright & Associates now owns 6,110 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 3,510 shares in the last quarter. Belvedere Trading LLC purchased a new stake in Aclaris Therapeutics in the first quarter worth $415,000. Assenagon Asset Management S.A. bought a new stake in Aclaris Therapeutics in the first quarter valued at $519,000. Finally, Virtu Financial LLC purchased a new position in Aclaris Therapeutics during the 4th quarter valued at $141,000. 59.10% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts.

Featured Article: S&P/TSX Index

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with's FREE daily email newsletter.